The Experts below are selected from a list of 234 Experts worldwide ranked by ideXlab platform
Tara A Mccannel - One of the best experts on this subject based on the ideXlab platform.
-
glaucoma after Iodine 125 brachytherapy for uveal melanoma incidence and risk factors
Journal of Glaucoma, 2020Co-Authors: Eunah Kim, Diana Salazar, Colin A Mccannel, Mitchell Kamrava, D J Demanes, J Lamb, Joseph Caprioli, Tara A MccannelAbstract:PReCIS:: A single-center retrospective review over a 10-year period discovered an 8.6% risk of developing secondary open-angle glaucoma, and a 6.7% risk of neovascular glaucoma after brachytherapy for uveal melanoma. Additional risk factors were identified. Purpose To report the incidence and identify risk factors for secondary open-angle glaucoma and neovascular glaucoma after Iodine-125 brachytherapy for uveal melanoma in a tertiary ocular oncology and glaucoma practice. Patients and methods Eyes of patients who had been diagnosed and treated with Iodine-12 brachytherapy for uveal melanoma over a 10-year period were included for review. Secondary open-angle glaucoma was defined as meeting the following criteria: at least 3 measurements of intraocular pressure (IOP) ≥21 mm Hg after the removal of the Iodine-125 plaque and an open angle on gonioscopy. Neovascular glaucoma was defined as meeting the following criteria: at least 3 measurements of IOP ≥21 mm Hg and neovascularization of the iris or anterior chamber angle. Cumulative incidence was calculated and survival analysis was used to analyze risk factors for both secondary open-angle glaucoma and neovascular glaucoma. Results A total of 374 eyes in patients diagnosed with uveal melanoma and treated with Iodine-125 brachytherapy were included in the study. Thirty-one eyes (8.6%) were diagnosed with secondary open-angle glaucoma and 25 eyes (6.7%) were diagnosed with neovascular glaucoma. Multivariate analysis identified the following risk factors for secondary open-angle glaucoma: older age, greater tumor size, iris location of uveal melanoma, higher baseline IOP, ciliary body involvement, and eyes having undergone combined brachytherapy with vitrectomy and silicone oil placement for radiation attenuation. The risk factors for neovascular glaucoma were as follows: greater tumor size, greater number of pack-years smoking history, pseudophakia, and higher grade of radiation retinopathy severity by fluorescein angiogram. Conclusions We have identified additional risk factors for the development of both secondary open-angle glaucoma and neovascular glaucoma in patients with uveal melanoma who have undergone Iodine-125 brachytherapy for local tumor control. The risk of secondary glaucoma is substantial. Close ophthalmic monitoring of patients is necessary for detection and timely treatment of glaucoma to maximize visual outcome.
-
23 mm Iodine 125 plaque for uveal melanoma benefit of vitrectomy and silicone oil on visual acuity
Graefes Archive for Clinical and Experimental Ophthalmology, 2016Co-Authors: Tara A Mccannel, Mitchell Kamrava, J Lamb, Jeffrey D Demanes, John Bartlett, Robert Almanzor, Melissa W Chun, Colin A MccannelAbstract:Purpose To review outcomes in mostly large uveal melanoma treated with a 23-mm-diameter Iodine-125 plaque, the largest size available at our center, and the influence of vitrectomy and silicone oil 1000 centistokes for radiation attenuation.
Colin A Mccannel - One of the best experts on this subject based on the ideXlab platform.
-
glaucoma after Iodine 125 brachytherapy for uveal melanoma incidence and risk factors
Journal of Glaucoma, 2020Co-Authors: Eunah Kim, Diana Salazar, Colin A Mccannel, Mitchell Kamrava, D J Demanes, J Lamb, Joseph Caprioli, Tara A MccannelAbstract:PReCIS:: A single-center retrospective review over a 10-year period discovered an 8.6% risk of developing secondary open-angle glaucoma, and a 6.7% risk of neovascular glaucoma after brachytherapy for uveal melanoma. Additional risk factors were identified. Purpose To report the incidence and identify risk factors for secondary open-angle glaucoma and neovascular glaucoma after Iodine-125 brachytherapy for uveal melanoma in a tertiary ocular oncology and glaucoma practice. Patients and methods Eyes of patients who had been diagnosed and treated with Iodine-12 brachytherapy for uveal melanoma over a 10-year period were included for review. Secondary open-angle glaucoma was defined as meeting the following criteria: at least 3 measurements of intraocular pressure (IOP) ≥21 mm Hg after the removal of the Iodine-125 plaque and an open angle on gonioscopy. Neovascular glaucoma was defined as meeting the following criteria: at least 3 measurements of IOP ≥21 mm Hg and neovascularization of the iris or anterior chamber angle. Cumulative incidence was calculated and survival analysis was used to analyze risk factors for both secondary open-angle glaucoma and neovascular glaucoma. Results A total of 374 eyes in patients diagnosed with uveal melanoma and treated with Iodine-125 brachytherapy were included in the study. Thirty-one eyes (8.6%) were diagnosed with secondary open-angle glaucoma and 25 eyes (6.7%) were diagnosed with neovascular glaucoma. Multivariate analysis identified the following risk factors for secondary open-angle glaucoma: older age, greater tumor size, iris location of uveal melanoma, higher baseline IOP, ciliary body involvement, and eyes having undergone combined brachytherapy with vitrectomy and silicone oil placement for radiation attenuation. The risk factors for neovascular glaucoma were as follows: greater tumor size, greater number of pack-years smoking history, pseudophakia, and higher grade of radiation retinopathy severity by fluorescein angiogram. Conclusions We have identified additional risk factors for the development of both secondary open-angle glaucoma and neovascular glaucoma in patients with uveal melanoma who have undergone Iodine-125 brachytherapy for local tumor control. The risk of secondary glaucoma is substantial. Close ophthalmic monitoring of patients is necessary for detection and timely treatment of glaucoma to maximize visual outcome.
-
23 mm Iodine 125 plaque for uveal melanoma benefit of vitrectomy and silicone oil on visual acuity
Graefes Archive for Clinical and Experimental Ophthalmology, 2016Co-Authors: Tara A Mccannel, Mitchell Kamrava, J Lamb, Jeffrey D Demanes, John Bartlett, Robert Almanzor, Melissa W Chun, Colin A MccannelAbstract:Purpose To review outcomes in mostly large uveal melanoma treated with a 23-mm-diameter Iodine-125 plaque, the largest size available at our center, and the influence of vitrectomy and silicone oil 1000 centistokes for radiation attenuation.
J Lamb - One of the best experts on this subject based on the ideXlab platform.
-
glaucoma after Iodine 125 brachytherapy for uveal melanoma incidence and risk factors
Journal of Glaucoma, 2020Co-Authors: Eunah Kim, Diana Salazar, Colin A Mccannel, Mitchell Kamrava, D J Demanes, J Lamb, Joseph Caprioli, Tara A MccannelAbstract:PReCIS:: A single-center retrospective review over a 10-year period discovered an 8.6% risk of developing secondary open-angle glaucoma, and a 6.7% risk of neovascular glaucoma after brachytherapy for uveal melanoma. Additional risk factors were identified. Purpose To report the incidence and identify risk factors for secondary open-angle glaucoma and neovascular glaucoma after Iodine-125 brachytherapy for uveal melanoma in a tertiary ocular oncology and glaucoma practice. Patients and methods Eyes of patients who had been diagnosed and treated with Iodine-12 brachytherapy for uveal melanoma over a 10-year period were included for review. Secondary open-angle glaucoma was defined as meeting the following criteria: at least 3 measurements of intraocular pressure (IOP) ≥21 mm Hg after the removal of the Iodine-125 plaque and an open angle on gonioscopy. Neovascular glaucoma was defined as meeting the following criteria: at least 3 measurements of IOP ≥21 mm Hg and neovascularization of the iris or anterior chamber angle. Cumulative incidence was calculated and survival analysis was used to analyze risk factors for both secondary open-angle glaucoma and neovascular glaucoma. Results A total of 374 eyes in patients diagnosed with uveal melanoma and treated with Iodine-125 brachytherapy were included in the study. Thirty-one eyes (8.6%) were diagnosed with secondary open-angle glaucoma and 25 eyes (6.7%) were diagnosed with neovascular glaucoma. Multivariate analysis identified the following risk factors for secondary open-angle glaucoma: older age, greater tumor size, iris location of uveal melanoma, higher baseline IOP, ciliary body involvement, and eyes having undergone combined brachytherapy with vitrectomy and silicone oil placement for radiation attenuation. The risk factors for neovascular glaucoma were as follows: greater tumor size, greater number of pack-years smoking history, pseudophakia, and higher grade of radiation retinopathy severity by fluorescein angiogram. Conclusions We have identified additional risk factors for the development of both secondary open-angle glaucoma and neovascular glaucoma in patients with uveal melanoma who have undergone Iodine-125 brachytherapy for local tumor control. The risk of secondary glaucoma is substantial. Close ophthalmic monitoring of patients is necessary for detection and timely treatment of glaucoma to maximize visual outcome.
-
23 mm Iodine 125 plaque for uveal melanoma benefit of vitrectomy and silicone oil on visual acuity
Graefes Archive for Clinical and Experimental Ophthalmology, 2016Co-Authors: Tara A Mccannel, Mitchell Kamrava, J Lamb, Jeffrey D Demanes, John Bartlett, Robert Almanzor, Melissa W Chun, Colin A MccannelAbstract:Purpose To review outcomes in mostly large uveal melanoma treated with a 23-mm-diameter Iodine-125 plaque, the largest size available at our center, and the influence of vitrectomy and silicone oil 1000 centistokes for radiation attenuation.
Mitchell Kamrava - One of the best experts on this subject based on the ideXlab platform.
-
glaucoma after Iodine 125 brachytherapy for uveal melanoma incidence and risk factors
Journal of Glaucoma, 2020Co-Authors: Eunah Kim, Diana Salazar, Colin A Mccannel, Mitchell Kamrava, D J Demanes, J Lamb, Joseph Caprioli, Tara A MccannelAbstract:PReCIS:: A single-center retrospective review over a 10-year period discovered an 8.6% risk of developing secondary open-angle glaucoma, and a 6.7% risk of neovascular glaucoma after brachytherapy for uveal melanoma. Additional risk factors were identified. Purpose To report the incidence and identify risk factors for secondary open-angle glaucoma and neovascular glaucoma after Iodine-125 brachytherapy for uveal melanoma in a tertiary ocular oncology and glaucoma practice. Patients and methods Eyes of patients who had been diagnosed and treated with Iodine-12 brachytherapy for uveal melanoma over a 10-year period were included for review. Secondary open-angle glaucoma was defined as meeting the following criteria: at least 3 measurements of intraocular pressure (IOP) ≥21 mm Hg after the removal of the Iodine-125 plaque and an open angle on gonioscopy. Neovascular glaucoma was defined as meeting the following criteria: at least 3 measurements of IOP ≥21 mm Hg and neovascularization of the iris or anterior chamber angle. Cumulative incidence was calculated and survival analysis was used to analyze risk factors for both secondary open-angle glaucoma and neovascular glaucoma. Results A total of 374 eyes in patients diagnosed with uveal melanoma and treated with Iodine-125 brachytherapy were included in the study. Thirty-one eyes (8.6%) were diagnosed with secondary open-angle glaucoma and 25 eyes (6.7%) were diagnosed with neovascular glaucoma. Multivariate analysis identified the following risk factors for secondary open-angle glaucoma: older age, greater tumor size, iris location of uveal melanoma, higher baseline IOP, ciliary body involvement, and eyes having undergone combined brachytherapy with vitrectomy and silicone oil placement for radiation attenuation. The risk factors for neovascular glaucoma were as follows: greater tumor size, greater number of pack-years smoking history, pseudophakia, and higher grade of radiation retinopathy severity by fluorescein angiogram. Conclusions We have identified additional risk factors for the development of both secondary open-angle glaucoma and neovascular glaucoma in patients with uveal melanoma who have undergone Iodine-125 brachytherapy for local tumor control. The risk of secondary glaucoma is substantial. Close ophthalmic monitoring of patients is necessary for detection and timely treatment of glaucoma to maximize visual outcome.
-
23 mm Iodine 125 plaque for uveal melanoma benefit of vitrectomy and silicone oil on visual acuity
Graefes Archive for Clinical and Experimental Ophthalmology, 2016Co-Authors: Tara A Mccannel, Mitchell Kamrava, J Lamb, Jeffrey D Demanes, John Bartlett, Robert Almanzor, Melissa W Chun, Colin A MccannelAbstract:Purpose To review outcomes in mostly large uveal melanoma treated with a 23-mm-diameter Iodine-125 plaque, the largest size available at our center, and the influence of vitrectomy and silicone oil 1000 centistokes for radiation attenuation.
Mark Bernstein - One of the best experts on this subject based on the ideXlab platform.
-
Brain necrosis after permanent low-activity Iodine-125 implants: case report and review of toxicity from focal radiation
Brain Tumor Pathology, 2000Co-Authors: Joseph Bampoc, Phil Leung, Normand Lapefriere, Mark BernsteinAbstract:Focal irradiation has emerged as a useful modality in the management of malignant brain tumors. Its main limitation is radiation necrosis. We report on the radiation dose distribution in the cerebellum of a patient who developed imaging and autopsy diagnosis of radiation necrosis after permanent Iodine-125 implants for a solitary osseous plasmacytoma of her left occipital condyle. A 55-year-old woman initially presented with neck and occipital pain and a lytic lesion of her left occipital condyle. A cytological diagnosis of solitary osseous plasmacytoma was made by transpharyngeal needle biopsy. After an initial course of external beam radiation, the patient required further treatment with systemic chemotherapy 21 months later for clinical and radiographic progression of her disease. She ultimately required subtotal surgical resection of an anaplastic plasmacytoma with intracranial extension. Permanent low-activity Iodine-125 seeds were implanted in the tumor cavity. Satisfactory local control was achieved. However, clinical and imaging signs of radiation damage appeared 28 months after Iodine-125 seed implantation. Progressive systemic myeloma led to her death 11 years after presentation and 9 years after seed implantation. Radiation dose distribution is described, with a discussion of toxicity from focal radiation dose escalation.
-
protection of Iodine 125 brachytherapy brain injury in the rat with the 21 aminosteroid u 74389f
Neurosurgery, 1992Co-Authors: Mark Bernstein, Howard J Ginsberg, Jennifer GlenAbstract:: Radiation protection was studied in a rat brachytherapy brain injury model. Radiation lesions were produced by stereotactic placement of high-activity Iodine-125 seeds on the frontal lobe of F-344 rats. A minimum dose of 80 Gy was delivered to a 5.5-mm-radius volume. Radiation damage was evaluated 24 h after removal of the seeds by T1-weighted gadolinium-enhanced magnetic resonance imaging on a 1.5-T unit. Computerized three-dimensional reconstruction of the lesions seen on magnetic resonance imaging was performed to calculate the volume of radiation injury. Two experiments were performed with rats of different weights (mean, 300 g; mean, 180 g). All animals underwent surgical placement of an indwelling internal jugular catheter before brachytherapy. Treated animals received the 21-aminosteroid U-74389F 5 mg/kg intravenously every 6 hours during the implant and for 24 hours after the removal of the Iodine-125 seed. Control animals were administered vehicle only. In both experiments, a statistically significant reduction in volume of radiation damage was observed in the U-74389F-treated group compared with the control group.
